Humacyte (NASDAQ:HUMA) Earns Neutral Rating from Piper Sandler

Piper Sandler reiterated their neutral rating on shares of Humacyte (NASDAQ:HUMA – Free Report) in a research note issued to investors on Tuesday morning, Benzinga reports. The brokerage currently has a $4.00 price objective on the stock. Several other equities research analysts also recently commented on HUMA. HC Wainwright started coverage on shares of Humacyte […]

Related Keywords

Nevada ,United States ,American ,Piper Sandler ,Humacyte Inc ,Victory Capital Management Inc ,American International Group Inc ,Tower Research Capital ,Humacyte Company Profile ,Whittier Trust Co ,Nevada Inc ,Free Report ,Get Free Report ,Research Capital ,International Group ,Capital Management ,Bayesian Capital Management ,Humacyte Daily ,Humacyte ,Nasdaq Huma ,Huma ,Medical ,Reiterated Rating ,